Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxem Hib versus Hiberix in healthy children aged 13-59 months
2014-005246-22Phase 3
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Haemophilus b conjugate vaccine and haemophilus influenzae type b vaccine in Haemophilus influenzae type b disease (Hib) (2 arms), sponsored by Novartis. Primary endpoint: Anti-PRP seroprotection at 0.15 micrograms/mL.
02
Drugs
Haemophilus b conjugate vaccinehaemophilus influenzae type b vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2014-005246-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005246-22.